MDM2 and sarcoma: MDM2 gene amplification serves as the strongest predictive biomarker, defining a patient population with demonstrated susceptibility to MDM2 inhibition, particularly in sarcomas such as dedifferentiated liposarcoma, where near-universal amplification occurs (Ray-Coquard et al., 2012).